Kimura et al. found CXCR4 was associated with cell proliferation and tumorigenicity, concluding that CXCR4 is the marker of synovial sarcoma-initiating cells, a new biomarker for prognosis and a new potential therapeutic target (28). This evidence concerns the gene CXCR4 and synovial sarcoma.